ArticleJournal of gastroenterology and hepatology2026
Is Routine Interruption of Direct Oral Anticoagulants Necessary during Colorectal Endoscopic Mucosal Resection and Hot Snare Polypectomy? A Multicenter Propensity-Matched Study.
Article in Journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
BACKGROUND AND
aimsColorectal endoscopic mucosal resection (EMR) and hot snare polypectomy (HSP) are high-bleeding-risk endoscopic procedures, and most clinical guidelines recommend stopping direct oral anticoagulants (DOACs) temporarily or switching to heparin-bridging therapy (HBT). However, existing evidence is largely derived from cohorts that combine warfarin and DOAC users or include substantial use of HBT, and data directly comparing the continuation versus interruption of DOACs are limited. We aimed to assess whether periprocedural DOAC interruption reduces delayed postpolypectomy bleeding (DPPB) in patients undergoing EMR/HSP.
methodsConsecutive patients receiving DOAC therapy who underwent colorectal EMR or HSP between April 2020 and March 2024 were included in this retrospective study. The patients were classified into continuation and interruption groups following periprocedural DOAC management. Propensity score matching (PSM) was conducted using clinically relevant variables. The primary outcome was DPPB within 28 days.
resultsOverall, 691 patients who were receiving DOACs underwent EMR/HSP, and 146 matched pairs were analyzed. After PSM, covariate balance between the groups was improved. DPPB occurred in six patients (4.1%) in the interruption group and three patients (2.1%) in the continuation group (p = 0.501; absolute risk difference: 2.05% [95% confidence interval, -1.90%-6.01%]). No thromboembolic events were observed.
conclusionsDOAC continuation may not substantially increase DPPB risk compared with 1-day DOAC interruption in patients undergoing colorectal EMR/HSP. However, the small number of bleeding events and wide confidence intervals mean that a clinically meaningful difference cannot be excluded. Further prospective studies are needed to determine the optimal periprocedural DOAC management strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.